Wyeth Wydase discontinued
Wyeth has discontinued production of ocular surgery treatment Wydase (hyaluronidase). Wydase was manufactured at the company's Marietta, Penn. facility, which has been under an FDA consent decree since October 2000 (1"The Pink Sheet" Oct. 9, 2000, p. 3). Wyeth informed FDA of the discontinuation in the fourth quarter of 2000, but agreed to continue to manufacture the product until an alternate supplier of hyaluronidase was found...
You may also be interested in...
ISTA Pharmaceuticals will delay full-scale launch of its spreading agent Vitrase until it receives approval for a more convenient vial form
Wyeth-Ayerst would have to pay the government 18.5% of future net sales from products manufactured at its Marietta, Penn. facility if it fails to meet a timeline for bringing the plant into compliance with current Good Manufacturing Practices under an Oct. 3 consent decree with FDA.
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.